Price
$68.7
Decreased by -7.52%
Dollar Volume
70.16 M
ADR%
5.56
Earnings Report Date (estimate)
Feb 27, 23 (-1.14)
Market Cap.
2.98 B
Shares Float
35.41 M
Shares Outstanding
43.43 M
Beta
2.03
Price / Earnings
-18.47
BPR
466.46
20D Range
59.82 76.63
50D Range
55.31 82.00
200D Range
20.64 82.00
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 7, 22 -1.07
Decreased by -15.05%
-1.08
Increased by +0.93%
Aug 9, 22 -1.06
Decreased by -23.26%
-1.24
Increased by +14.52%
May 2, 22 -1.03
Decreased by -32.05%
-1.00
Decreased by -3.00%
Mar 1, 22 -0.90
Decreased by -15.38%
-1.03
Increased by +12.62%
Nov 8, 21 -0.93
Decreased by -52.46%
-0.95
Increased by +2.11%
Aug 9, 21 -0.86
Decreased by -75.51%
-0.96
Increased by +10.42%
May 10, 21 -0.78
Increased by +11.36%
-0.87
Increased by +10.34%
Mar 1, 21 -0.78
Decreased by -9.86%
-0.76
Decreased by -2.63%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 16.85 M
Increased by +N/A%
-44.82 M
Decreased by -28.50%
Decreased by -266.08%
Decreased by N/A%
Jun 30, 22 8.82 M
Increased by +N/A%
-41.44 M
Decreased by -28.36%
Decreased by -469.84%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-39.63 M
Decreased by -35.45%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-33.98 M
Decreased by -16.50%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-34.88 M
Decreased by -52.16%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-32.28 M
Decreased by -76.16%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-29.26 M
Increased by +9.93%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-29.16 M
Decreased by -17.57%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.